Welcome to the Buhrlage Lab

Our mission is to develop first-in-class inhibitors and prototype drugs against deubiquitinating enzymes. We harness the power of diverse and complementary techniques for inhibitor discovery: high throughput screening, chemoproteomics, medicinal chemistry, biochemistry, computational chemistry, bioinformatics, and structural analysis. We utilize these inhibitors for phenotypic screens against disease systems encompassing oncology, neurodegeneration, and infectious diseases. Our work has led to a potent and selective USP7 inhibitor that elicits cancer cell death through a p53-dependent mechanism.

---